The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children

被引:11
|
作者
Walter, Emmanuel B. [1 ,2 ]
Hornik, Christoph P. [2 ]
Grohskopf, Lisa [3 ]
McGee, Charles E. [1 ]
Todd, Christopher A. [1 ]
Museru, Oidda I. [4 ]
Harrington, Lynn [1 ]
Broder, Karen R. [4 ]
机构
[1] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA
[2] Duke Univ, Sch Med, Dept Pediat, Duke Clin Res Inst, Durham, NC USA
[3] Ctr Dis Control & Prevent, Influenza Div, Epidemiol & Prevent Branch, Atlanta, GA USA
[4] Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Atlanta, GA USA
关键词
Antipyretics; Fever; Immunity; Influenza; Vaccine; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; FEBRILE SEIZURES; UNITED-STATES; RISK; RECOMMENDATIONS; REACTOGENICITY; ACETAMINOPHEN; PREVENTION; SAFETY;
D O I
10.1016/j.vaccine.2017.10.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Antipyretics reduce fever following childhood vaccinations; after inactivated influenza vaccine (IIV) they might ameliorate fever and thereby decrease febrile seizure risk, but also possibly blunt the immune response. We assessed the effect of antipyretics on immune responses and fever following IIV in children ages 6 through 47 months. Methods: Over the course of three seasons, one hundred forty-two children, receiving either a single or the first of 2 recommended doses of IIV, were randomized to receive either oral acetaminophen suspension (n = 59) or placebo (n = 59) (double-blinded) or ibuprofen (n = 24) (open-label) immediately following IIV and every 4-8 h thereafter for 24 h. Blood samples were obtained at enrollment and 4 weeks following the last recommended IIV dose. Responses to IIV were assessed by hemagglutination inhibition assay (HAI). Seroprotection was defined as an HAI titer >= 1:40 and seroconversion as a titer >= 1:40 if baseline titer <1:10 or four-fold rise if baseline titer >= 1:10. Participants were monitored for fever and other solicited symptoms on the day of and day following IIV. Results: Significant differences in seroconversion and post-vaccination seroprotection were not observed between children included in the different antipyretic groups and the placebo group for the vaccine antigens included in IIV over the course of the studies. Frequencies of solicited symptoms, including fever, were similar between treatment groups and the placebo group. Conclusions: Significant blunting of the immune response was not observed when antipyretics were administered to young children receiving IIV. Studies with larger sample sizes are needed to definitively establish the effect of antipyretics on IIV immunogenicity. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6664 / 6671
页数:8
相关论文
共 50 条
  • [21] Benefits and Risks of Live Attenuated Influenza Vaccine in Young Children
    Oster, Gerry
    Weycker, Derek
    Edelsberg, John
    Nichol, Kristin L.
    Klein, Jerome O.
    Belshe, Robert B.
    AMERICAN JOURNAL OF MANAGED CARE, 2010, 16 (09) : E235 - E244
  • [22] Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial
    Loeb, Mark
    Russell, Margaret L.
    Kelly-Stradiotto, Caralyn
    Fuller, Nola
    Fonseca, Kevin
    Earn, David J. D.
    Chokani, Khami
    Babiuk, Lorne
    Neupane, Binod
    Singh, Pardeep
    Pullenayegum, Eleanor
    VACCINE, 2021, 39 (47) : 6843 - 6851
  • [23] Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010
    Choe, Young June
    Cho, Heeyeon
    Kim, Sung Nam
    Bae, Geun-Ryang
    Lee, Jong-Koo
    VACCINE, 2011, 29 (44) : 7727 - 7732
  • [24] Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts
    Koutsonanos, Dimitrios G.
    Esser, E. Stein
    McMaster, Sean R.
    Kalluri, Priya
    Lee, Jeong-Woo
    Prausnitz, Mark R.
    Skountzou, Ioanna
    Denning, Timothy L.
    Kohlmeier, Jacob E.
    Compans, Richard W.
    VACCINE, 2015, 33 (37) : 4675 - 4682
  • [25] Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan
    Sugaya, N.
    Shinjoh, M.
    Kawakami, C.
    Yamaguchi, Y.
    Yoshida, M.
    Baba, H.
    Ishikawa, M.
    Kono, M.
    Sekiguchi, S.
    Kimiya, T.
    Mitamura, K.
    Fujino, M.
    Komiyama, O.
    Yoshida, N.
    Tsunematsu, K.
    Narabayashi, A.
    Nakata, Y.
    Sato, A.
    Taguchi, N.
    Fujita, H.
    Toki, M.
    Myokai, M.
    Ookawara, I.
    Takahashi, T.
    EUROSURVEILLANCE, 2016, 21 (42) : 2 - 14
  • [26] Differential gene expression in peripheral blood mononuclear cells from children immunized with inactivated influenza vaccine
    Alcorn, John F.
    Avula, Raghunandan
    Chakka, Anish B.
    Schwarzmann, William E.
    Nowalk, Mary Patricia
    Lin, Chyongchiou Jeng
    Ortiz, Marianna A.
    Horne, William T.
    Chandran, Uma R.
    Nagg, Jennifer P.
    Zimmerman, Richard K.
    Cole, Kelly S.
    Moehling, Krissy K.
    Martin, Judith M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (08) : 1782 - 1790
  • [27] Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults
    Hakim, Hana
    Allison, Kim J.
    Van De Velde, Lee-Ann
    Li, Yimei
    Flynn, Patricia M.
    McCullers, Jonathan A.
    VACCINE, 2012, 30 (05) : 879 - 885
  • [28] Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
    Jain, Varsha K.
    Domachowske, Joseph B.
    Wang, Long
    Ofori-Anyinam, Opokua
    Rodriguez-Weber, Miguel A.
    Leonardi, Michael L.
    Klein, Nicola P.
    Schlichter, Gary
    Jeanfreau, Robert
    Haney, Byron L.
    Chu, Laurence
    Harris, Jo-Ann S.
    Sarpong, Kwabena O.
    Micucio, Amanda C.
    Soni, Jyoti
    Chandrasekaran, Vijayalakshmi
    Li, Ping
    Innis, Bruce L.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2017, 6 (01) : 9 - 19
  • [29] A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults
    Atmar, Robert L.
    Keitel, Wendy A.
    Cate, Thomas R.
    Munoz, Flor M.
    Ruben, Fred
    Couch, Robert B.
    VACCINE, 2007, 25 (29) : 5367 - 5373
  • [30] Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine
    Muszkat, M
    Greenbaum, E
    Ben-Yehuda, A
    Oster, M
    Yeu'l, E
    Heimann, S
    Levy, R
    Friedman, G
    Zakay-Rones, Z
    VACCINE, 2003, 21 (11-12) : 1180 - 1186